Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies

1. Schwartzberg L, Kim ES, Liu D, Schrag D. Precision Oncology: who, how, what, when, and when not? Am Soc Clin Oncol Educ Book 2017; 37: 160–9. doi: 10.1200/EDBK_174176 SchwartzbergL KimES LiuD SchragD Precision Oncology: who, how, what, when, and when not? Am Soc Clin Oncol Educ Book 2017 37 160 9 10.1200/EDBK_174176 Open DOISearch in Google Scholar

2. Schettini F, Prat A. Dissecting the biological heterogeneity of HER2-positive breast cancer. Breast 2021; 59: 339–50. doi: 10.1016/j.breast.2021.07.019 SchettiniF PratA Dissecting the biological heterogeneity of HER2-positive breast cancer Breast 2021 59 339 50 10.1016/j.breast.2021.07.019 Open DOISearch in Google Scholar

3. Yang C, Brezden-Masley C, Joy AA, Sehdev S, Modi S, Simmon C, et al. Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm. Ther Adv Med Oncol 2023; 15: 1–19. doi: 10.1177/17588359231175440 YangC Brezden-MasleyC JoyAA SehdevS ModiS SimmonC Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm Ther Adv Med Oncol 2023 15 1 19 10.1177/17588359231175440 Open DOISearch in Google Scholar

4. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Saurer AG, et al. Breast cancer statistics, 2019. CA Cancer J Clin 2019; 69: 438–51. doi: 10.3322/caac.21583 DeSantisCE MaJ GaudetMM NewmanLA MillerKD SaurerAG Breast cancer statistics, 2019 CA Cancer J Clin 2019 69 438 51 10.3322/caac.21583 Open DOISearch in Google Scholar

5. Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardiat A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer Ann Oncol 2023; 34: 645–59. doi: 10.1016/j.annonc.2023.05.008 TarantinoP VialeG PressMF HuX Penault-LlorcaF BardiatA ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer Ann Oncol 2023 34 645 59 10.1016/j.annonc.2023.05.008 Open DOISearch in Google Scholar

6. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-Low breast cancer: pathological and clinical landscape. J Clin Oncol 2020; 38: 1951–62. doi: 10.1200/JCO.19.02488 TarantinoP HamiltonE TolaneySM CortesJ MorgantiS FerraroE HER2-Low breast cancer: pathological and clinical landscape J Clin Oncol 2020 38 1951 62 10.1200/JCO.19.02488 Open DOISearch in Google Scholar

7. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists Guideline Update. J Clin Oncol 2023; 41: 3867–72. doi: 10.1200/jco.22.02864 WolffAC SomerfieldMR DowsettM HammondMEH HayesDF McShaneLM Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists Guideline Update J Clin Oncol 2023 41 3867 72 10.1200/jco.22.02864 Open DOISearch in Google Scholar

8. Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019; 20: 1124–35. doi: 10.1016/S1470-2045(19)30328-6 BanerjiU van HerpenCML SauraC ThistlethwaiteF LordS MorenoV Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study Lancet Oncol 2019 20 1124 35 10.1016/S1470-2045(19)30328-6 Open DOISearch in Google Scholar

9. Wang J, Liu Y, Zhang Q, Feng J, Chen X, Han Y, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. [abstract]. J Clin Oncol 2021; 39(15 Suppl): 1022. doi: 10.1200/JCO.2021.39.15_suppl.1022 WangJ LiuY ZhangQ FengJ ChenX HanY RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. [abstract] J Clin Oncol 2021 39 15 Suppl 1022 10.1200/JCO.2021.39.15_suppl.1022 Open DOISearch in Google Scholar

10. Xu B, Wang J, Fang J, Chen X, Han Y, Li Q, et al. Abstract PD4-06: early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer. [abstract]. San Antonio Breast Cancer Symposium; December 10–14, 2019; San Antonio, Texas, 2019 Dec 10–14. Cancer Res 2020; 80(4 Suppl): PD4-06. doi: 10.1158/1538-7445.SABCS19-PD4-06 XuB WangJ FangJ ChenX HanY LiQ Abstract PD4-06: early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer. [abstract]. San Antonio Breast Cancer Symposium; December 10–14, 2019; San Antonio, Texas, 2019 Dec 10–14 Cancer Res 2020 80 4 Suppl PD4-06 10.1158/1538-7445.SABCS19-PD4-06 Open DOISearch in Google Scholar

11. Corti C, Giugliano F, Nicolò E, Ascione L, Curigliano G. Antibody-drug conjugates for the treatment of breast cancer. Cancers 2021; 13: 1–23. doi: 10.3390/cancers13122898 CortiC GiuglianoF NicolòE AscioneL CuriglianoG Antibody-drug conjugates for the treatment of breast cancer Cancers 2021 13 1 23 10.3390/cancers13122898 Open DOISearch in Google Scholar

12. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med 2022; 387: 9–20. doi: 10.1056/nejmoa2203690 ModiS JacotW YamashitaT SohnJ VidalM TokunagaE Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer N Engl J Med 2022 387 9 20 10.1056/nejmoa2203690 Open DOISearch in Google Scholar

13. Holthuis EI, Vondeling GT, Kuiper JG, Dezentje V, Rosenlund M, Overbeek JA, et al. Real-world data of HER2-low metastatic breast cancer: a population based cohort study. Breast 2022; 66: 278–84. doi: 10.1016/j.breast.2022.11.003 HolthuisEI VondelingGT KuiperJG DezentjeV RosenlundM OverbeekJA Real-world data of HER2-low metastatic breast cancer: a population based cohort study Breast 2022 66 278 84 10.1016/j.breast.2022.11.003 Open DOISearch in Google Scholar

14. Venetis K, Crimini E, Sajjadi E, Corti C, Guerino-Rocco E, Viale G, et al. HER2 Low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci 2022; 9: 1–12. doi: 10.3389/fmolb.2022.834651 VenetisK CriminiE SajjadiE CortiC Guerino-RoccoE VialeG HER2 Low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer Front Mol Biosci 2022 9 1 12 10.3389/fmolb.2022.834651 Open DOISearch in Google Scholar

15. Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. Breast 2023; 67: 116–23. doi: 10.1016/j.breast.2023.01.005 SchlamI TolaneySM TarantinoP How I treat HER2-low advanced breast cancer Breast 2023 67 116 23 10.1016/j.breast.2023.01.005 Open DOISearch in Google Scholar

16. Schettini F, Chic N, Brasó-Maristany F, Pare L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 2021; 7: 1. doi: 10.1038/s41523-020-00208-2 SchettiniF ChicN Brasó-MaristanyF PareL PascualT ConteB Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer NPJ Breast Cancer 2021 7 1 10.1038/s41523-020-00208-2 Open DOISearch in Google Scholar

17. Nicolò E, Boscolo Bielo L, Curigliano G, Tarantino P. The HER2-low revolution in breast oncology: steps forward and emerging challenges. Ther Adv Med Oncol 2023; 15: 1–16. doi: 10.1177/17588359231152842 NicolòE Boscolo BieloL CuriglianoG TarantinoP The HER2-low revolution in breast oncology: steps forward and emerging challenges Ther Adv Med Oncol 2023 15 1 16 10.1177/17588359231152842 Open DOISearch in Google Scholar

18. Rassy E, Rached L, Pistilli B. Antibody drug conjugates targeting HER2: clinical development in metastatic breast cancer. Breast 2022; 66: 217–26. doi: 10.1016/j.breast.2022.10.016 RassyE RachedL PistilliB Antibody drug conjugates targeting HER2: clinical development in metastatic breast cancer Breast 2022 66 217 26 10.1016/j.breast.2022.10.016 Open DOISearch in Google Scholar

19. Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res 2021; 23: 84. doi: 10.1186/s13058-021-01459-y FerraroE DragoJZ ModiS Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions Breast Cancer Res 2021 23 84 10.1186/s13058-021-01459-y Open DOISearch in Google Scholar

20. Popović M, Silovski T, Križić M, Dedić Plavetić N. HER2 Low breast cancer: a new subtype or a trojan for cytotoxic drug delivery? Int J Mol Sci 2023; 24: 8206. doi: 10.3390/ijms24098206 PopovićM SilovskiT KrižićM Dedić PlavetićN HER2 Low breast cancer: a new subtype or a trojan for cytotoxic drug delivery? Int J Mol Sci 2023 24 8206 10.3390/ijms24098206 Open DOISearch in Google Scholar

21. Newton M, Scott K, Troein P. EFPIA Patients W.A.I.T. indicator 2021 survey. [internet]. IQVIA; 2022. [cited 2023 Dec 15]. Available at: https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf NewtonM ScottK TroeinP EFPIA Patients W.A.I.T. indicator 2021 survey. [internet] IQVIA 2022 [cited 2023 Dec 15]. Available at: https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf Search in Google Scholar

22. Ades F, Senterre C, Zardavas D, De Azambuja E, Popescu R, Piccart M. Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. PLoS One 2017; 12: 1–11. doi: 10.1371/journal.pone.0172351 AdesF SenterreC ZardavasD De AzambujaE PopescuR PiccartM Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA PLoS One 2017 12 1 11 10.1371/journal.pone.0172351 Open DOISearch in Google Scholar

23. Trapani D, Curigliano G, Eniu A. Breast cancer: reimbursement policies and adoption of new therapeutic agents by national health systems. Breast Care 2019; 14: 373–81. doi: 10.1159/000502637 TrapaniD CuriglianoG EniuA Breast cancer: reimbursement policies and adoption of new therapeutic agents by national health systems Breast Care 2019 14 373 81 10.1159/000502637 Open DOISearch in Google Scholar

24. Hofmarcher T, Szilagyiova P, Gustafsson A, Dolezal T, Rutkowski P, Baxter C, et al. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit. ESMO Open 2023; 8: 101593. doi: 10.1016/j.esmoop.2023.101593 HofmarcherT SzilagyiovaP GustafssonA DolezalT RutkowskiP BaxterC Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit ESMO Open 2023 8 101593 10.1016/j.esmoop.2023.101593 Open DOISearch in Google Scholar

25. International Agency for Research on Cancer, World Health Organization. Breast cancer. Population Fact Sheets. [internet]. 2021. [cited 2023 Dec 16] Available at: https://gco.iarc.fr/today/fact-sheets-populations International Agency for Research on Cancer, World Health Organization Breast cancer. Population Fact Sheets. [internet] 2021 [cited 2023 Dec 16] Available at: https://gco.iarc.fr/today/fact-sheets-populations Search in Google Scholar

26. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 2022; 66: 15–23. doi: 10.1016/j.breast.2022.08.010 ArnoldM MorganE RumgayH MafraA SinghD LaversanneM Current and future burden of breast cancer: Global statistics for 2020 and 2040 Breast 2022 66 15 23 10.1016/j.breast.2022.08.010 Open DOISearch in Google Scholar

27. Vrdoljak E, Bodoky G, Jassem J, Popescu RA, Mardiak J, Pirker P, et al. Cancer control in central and eastern europe: current situation and recommendations for improvement. Oncologist 2016; 21: 1183–90. doi: 10.1634/theoncologist.2016-0137 VrdoljakE BodokyG JassemJ PopescuRA MardiakJ PirkerP Cancer control in central and eastern europe: current situation and recommendations for improvement Oncologist 2016 21 1183 90 10.1634/theoncologist.2016-0137 Open DOISearch in Google Scholar

28. Vrdoljak E, Bodoky G, Jassem J, Popescu R, Pirker R, Čufer T, et al. Expenditures on oncology drugs and cancer mortality-to-incidence ratio in central and Eastern Europe. Oncologist 2019; 24: e30–7. doi: 10.1634/theoncologist.2018-0093 VrdoljakE BodokyG JassemJ PopescuR PirkerR ČuferT Expenditures on oncology drugs and cancer mortality-to-incidence ratio in central and Eastern Europe Oncologist 2019 24 e30 7 10.1634/theoncologist.2018-0093 Open DOISearch in Google Scholar

29. Azadnajafabad S, Saeedi Moghaddam S, Mohammadi E, Delazar S, Rashedi S, Baradaran HR, et al. Patterns of better breast cancer care in countries with higher human development index and healthcare expenditure: insights from GLOBOCAN 2020. Front Public Heal 2023; 11: 1137286. doi: 10.3389/fpubh.2023.1137286 AzadnajafabadS Saeedi MoghaddamS MohammadiE DelazarS RashediS BaradaranHR Patterns of better breast cancer care in countries with higher human development index and healthcare expenditure: insights from GLOBOCAN 2020 Front Public Heal 2023 11 1137286 10.3389/fpubh.2023.1137286 Open DOISearch in Google Scholar

30. Koczkodaj P, Sulkowska U, Gotlib J, Mańczuk M. Breast cancer mortality trends in Europe among women in perimenopausal and postmenopausal age (45+). Arch Med Sci 2020; 16: 146–56. doi: 10.5114/aoms.2019.85198 KoczkodajP SulkowskaU GotlibJ MańczukM Breast cancer mortality trends in Europe among women in perimenopausal and postmenopausal age (45+) Arch Med Sci 2020 16 146 56 10.5114/aoms.2019.85198 Open DOISearch in Google Scholar

31. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšič, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023–75. doi: 10.1016/S0140-6736(17)33326-3 AllemaniC MatsudaT Di CarloV HarewoodR MatzM Nikšič Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries Lancet 2018 391 1023 75 10.1016/S0140-6736(17)33326-3 Open DOISearch in Google Scholar

32. Zadnik V, Zagar T, Lokar K, Tomsic S, Konjevic AD, Zakotnik B. Trends in population-based cancer survival in Slovenia. Radiol Oncol 2021; 55: 42–9. doi: 10.2478/raon-2021-0003 ZadnikV ZagarT LokarK TomsicS KonjevicAD ZakotnikB Trends in population-based cancer survival in Slovenia Radiol Oncol 2021 55 42 9 10.2478/raon-2021-0003 Open DOISearch in Google Scholar

33. Vrdoljak E, Gligorov J, Wierinck L, Conte PF, Dr Greve J, Meunier F, et al. Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. Breast 2021; 55: 79–90. doi: 10.1016/j.breast.2020.12.005 VrdoljakE GligorovJ WierinckL ContePF Dr GreveJ MeunierF Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe Breast 2021 55 79 90 10.1016/j.breast.2020.12.005 Open DOISearch in Google Scholar

34. ECIS - European cancer information system. Cancer Factsheets in EU-27 countries - 2020. Estimates of cancer incidence and mortality in 2020. Joint research centre. 2020. Available at: https://ecis.jrc.ec.europa.eu/ ECIS - European cancer information system Cancer Factsheets in EU-27 countries - 2020. Estimates of cancer incidence and mortality in 2020 Joint research centre 2020 Available at: https://ecis.jrc.ec.europa.eu/ Search in Google Scholar

35. Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, et al. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Res 2021; 23: 1–9. doi: 10.1186/s13058-021-01492-x GampenriederSP RinnerthalerG TinchonC PetzerA BalicM HeiblS Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry Breast Cancer Res 2021 23 1 9 10.1186/s13058-021-01492-x Open DOISearch in Google Scholar

36. Drev P, Blatnik O, Blazina J, Contreras J, Gašljević G, et al. [Determinations on 15,184 consecutive samples from the Oncology Institute in the period 2006 to 2021]. [Slovenian]. [internet]. 2021. p. 169–70. Available at: https://dirros.openscience.si/Dokument.php?id=21665&lang=slv DrevP BlatnikO BlazinaJ ContrerasJ GašljevićG [Determinations on 15,184 consecutive samples from the Oncology Institute in the period 2006 to 2021]. [Slovenian]. [internet] 2021 169 70 Available at: https://dirros.openscience.si/Dokument.php?id=21665&lang=slv Search in Google Scholar

37. Auprih M, Gazic B, Drev P, Borstnar S. The frequency of HER2-low breast cancer among patients diagnosed at the Institute of Oncology Ljubljana from 2011 to 2021. Fourth Regional Congress of Medical Oncology - REKONIO 2023. Ljubljana, 2023 Sep 7–9. In: Regional Congress of Medical Oncology REKONIO; 2023. p. 63–4. Ljubljana: Slovenian Medical Association-Section for Medical Oncology, Oncology Institute of Ljubljana, REKOG. Available at: https://rekogconference.com AuprihM GazicB DrevP BorstnarS The frequency of HER2-low breast cancer among patients diagnosed at the Institute of Oncology Ljubljana from 2011 to 2021. Fourth Regional Congress of Medical Oncology - REKONIO 2023. Ljubljana, 2023 Sep 7–9 In: Regional Congress of Medical Oncology REKONIO 2023 63 4 Ljubljana Slovenian Medical Association-Section for Medical Oncology, Oncology Institute of Ljubljana, REKOG Available at: https://rekogconference.com Search in Google Scholar

38. Bergeron A, Bertaut A, Beltjens F, Charon-Barra C, Amet A, Jankowski C, et al. Anticipating changes in the HER2 status of breast tumours with disease progression − towards better treatment decisions in the new era of HER2-low breast cancers. Br J Cancer 2023; 129: 1–13. doi: 10.1038/s41416-023-02287-x BergeronA BertautA BeltjensF Charon-BarraC AmetA JankowskiC Anticipating changes in the HER2 status of breast tumours with disease progression − towards better treatment decisions in the new era of HER2-low breast cancers Br J Cancer 2023 129 1 13 10.1038/s41416-023-02287-x Open DOISearch in Google Scholar

39. Dieci MV, Miglietta F. HER2: a never ending story. Lancet Oncol 2021; 22: 1051–52. doi: 10.1016/S1470-2045(21)00349-1 DieciMV MigliettaF HER2: a never ending story Lancet Oncol 2021 22 1051 52 10.1016/S1470-2045(21)00349-1 Open DOISearch in Google Scholar

40. Polidorio N, Veeravalli SS, Montagna G, Le T, Morrow M. Do HER2 low tumors have a distinct clinicopathologic phenotype? [abstract]. J Clin Oncol 2023; 41(16 Suppl): 570. doi: 10.1200/jco.2023.41.16_suppl.570 PolidorioN VeeravalliSS MontagnaG LeT MorrowM Do HER2 low tumors have a distinct clinicopathologic phenotype? [abstract] J Clin Oncol 2023 41 16 Suppl 570 10.1200/jco.2023.41.16_suppl.570 Open DOISearch in Google Scholar

41. Rugo HS, Wolf DM, Yau C, Petricoin E, Pohlmann PR, Pusztai L, et al. Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. [abstract]. J Clin Oncol 2023; 41(16 Suppl): 514. doi: 10.1200/jco.2023.41.16_suppl.514 RugoHS WolfDM YauC PetricoinE PohlmannPR PusztaiL Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. [abstract] J Clin Oncol 2023 41 16 Suppl 514 10.1200/jco.2023.41.16_suppl.514 Open DOISearch in Google Scholar

42. Djurmez O, Calamac M, Stanic N, Dimitrijevic M, Vukosavljevic J, Serovic K, et al,. Pathological complete response after neoadjuvantchemotherapy in patients with HER2 low and HER2 0 early breast cancer (eBC) experience from Insititute for Oncology and Radiology of Serbia (IORS). [abstract]. 18th St.Gallen International Breast Cancer Conference. 2023 Mar 15–18, Vienna, Austria. Breast 2023; 68(Suppl 1): S64. Available at: https://breast-ibcc-2023.elsevierdigitaledition.com/63/#zoom=true DjurmezO CalamacM StanicN DimitrijevicM VukosavljevicJ SerovicK Pathological complete response after neoadjuvantchemotherapy in patients with HER2 low and HER2 0 early breast cancer (eBC) experience from Insititute for Oncology and Radiology of Serbia (IORS). [abstract]. 18th St.Gallen International Breast Cancer Conference. 2023 Mar 15–18, Vienna, Austria Breast 2023 68 Suppl 1 S64 Available at: https://breast-ibcc-2023.elsevierdigitaledition.com/63/#zoom=true Search in Google Scholar

43. Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer 2021; 125: 164–75. doi: 10.1038/s41416-021-01328-7 LüöndF TiedeS ChristoforiG Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression Br J Cancer 2021 125 164 75 10.1038/s41416-021-01328-7 Open DOISearch in Google Scholar

44. Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol 2021; 72: 123–35. doi: 10.1016/j.semcancer.2020.02.016 MarchiòC AnnaratoneL MarquesA CasorzoL BerrinoE SapinoA Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond Semin Cancer Biol 2021 72 123 35 10.1016/j.semcancer.2020.02.016 Open DOISearch in Google Scholar

45. Hou Y, Nitta H, Li Z. HER2 intratumoral heterogeneity in breast cancer, an evolving concept. Cancers 2023; 15: 1–12. doi: 10.3390/cancers15102664 HouY NittaH LiZ HER2 intratumoral heterogeneity in breast cancer, an evolving concept Cancers 2023 15 1 12 10.3390/cancers15102664 Open DOISearch in Google Scholar

46. Bar Y, Dedeoglu AS, Fell GG, Moffett NJ, Bovraz B, Ly A, et al. Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): the impact of repeat biopsies. [abstract]. J Clin Oncol 2023; 41(16 Suppl): 1005. doi: 10.1200/JCO.2023.41.16_suppl.1005 BarY DedeogluAS FellGG MoffettNJ BovrazB LyA Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): the impact of repeat biopsies. [abstract] J Clin Oncol 2023 41 16 Suppl 1005 10.1200/JCO.2023.41.16_suppl.1005 Open DOISearch in Google Scholar

47. Miglietta F, Griguolo G, Bottosso M, Giarratano T, Mele ML, Fassan M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 2021; 7: 137. doi: 10.1038/s41523-021-00343-4 MigliettaF GriguoloG BottossoM GiarratanoT MeleML FassanM Evolution of HER2-low expression from primary to recurrent breast cancer NPJ Breast Cancer 2021 7 137 10.1038/s41523-021-00343-4 Open DOISearch in Google Scholar

48. Mosele MF, Lusque A, Dieras V, Ducoulombier A, Pistilli B, Bachelot T, et al. LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial. [abstract]. Ann Oncol 2022; 33(Suppl 3): S123. doi: 10.1016/j.annonc.2022.03.277 MoseleMF LusqueA DierasV DucoulombierA PistilliB BachelotT LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial. [abstract] Ann Oncol 2022 33 Suppl 3 S123 10.1016/j.annonc.2022.03.277 Open DOISearch in Google Scholar

49. Diéras V, Deluche E, Lusque A, Pistilli B, Bachelot T, Pierga JY, et al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY). [abstract]. SABCS 2021 San Antonio Breast Cancer Symposium, 2022 Feb 15. Cancer Res 2022; 82(4 Suppl): PD8-02. doi: 10.1158/1538-7445.SABCS21-PD8-02 DiérasV DelucheE LusqueA PistilliB BachelotT PiergaJY Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY). [abstract]. SABCS 2021 San Antonio Breast Cancer Symposium, 2022 Feb 15 Cancer Res 2022 82 4 Suppl PD8-02 10.1158/1538-7445.SABCS21-PD8-02 Open DOISearch in Google Scholar

50. Mazumder A, Shiao S, Haricharan S. HER2 activation and endocrine treatment resistance in HER2-negative breast cancer. Endocrinol 2021; 162: 1–18. doi: 10.1210/endocr/bqab153 MazumderA ShiaoS HaricharanS HER2 activation and endocrine treatment resistance in HER2-negative breast cancer Endocrinol 2021 162 1 18 10.1210/endocr/bqab153 Open DOISearch in Google Scholar

51. Pegram M, Jackisch C, Johnston SRD. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. NPJ Breast Cancer 2023; 9: 45. doi: 10.1038/s41523-023-00533-2 PegramM JackischC JohnstonSRD Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer NPJ Breast Cancer 2023 9 45 10.1038/s41523-023-00533-2 Open DOISearch in Google Scholar

52. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 2023; 22: 101–26. doi: 10.1038/s41573-022-00579-0 SwainSM ShastryM HamiltonE Targeting HER2-positive breast cancer: advances and future directions Nat Rev Drug Discov 2023 22 101 26 10.1038/s41573-022-00579-0 Open DOISearch in Google Scholar

53. Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol 2018; 36: 2105–22. doi: 10.1200/JCO.2018.77.8738 WolffAC Elizabeth Hale HammondM AllisonKH HarveyBE ManguPB BartlettJM Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline focused update J Clin Oncol 2018 36 2105 22 10.1200/JCO.2018.77.8738 Open DOISearch in Google Scholar

54. Sajjadi E, Guerini-Rocco E, De Camilli E, Pala O, Mazzarol G, Venetis K, et al. Pathological identification of HER2-low breast cancer: tips, tricks, and troubleshooting for the optimal test. Front Mol Biosci 2023; 10: 1–6. doi: 10.3389/fmolb.2023.1176309 SajjadiE Guerini-RoccoE De CamilliE PalaO MazzarolG VenetisK Pathological identification of HER2-low breast cancer: tips, tricks, and troubleshooting for the optimal test Front Mol Biosci 2023 10 1 6 10.3389/fmolb.2023.1176309 Open DOISearch in Google Scholar

55. Schnitt SJ, Tarantino P, Collins LC. The American Society of Clinical Oncology – College of American Pathologists Guideline update for human epidermal growth factor receptor 2 testing in breast cancer: how low can HER2 go? Arch Pathol Lab Med 2023; 147: 991–2. doi: 10.5858/arpa.2023-0187-ed SchnittSJ TarantinoP CollinsLC The American Society of Clinical Oncology – College of American Pathologists Guideline update for human epidermal growth factor receptor 2 testing in breast cancer: how low can HER2 go? Arch Pathol Lab Med 2023 147 991 2 10.5858/arpa.2023-0187-ed Open DOISearch in Google Scholar

56. Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med 2020; 54: 34–44. doi: 10.4132/jptm.2019.11.03 AhnS WooJW LeeK ParkSY HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation J Pathol Transl Med 2020 54 34 44 10.4132/jptm.2019.11.03 Open DOISearch in Google Scholar

57. Fernandez AI, Liu M, Bellizzi A, Brock J, Fadale O, Hanley K, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 2022; 8: 1–4. doi: 10.1001/jamaoncol.2021.7239 FernandezAI LiuM BellizziA BrockJ FadaleO HanleyK Examination of low ERBB2 protein expression in breast cancer tissue JAMA Oncol 2022 8 1 4 10.1001/jamaoncol.2021.7239 Open DOISearch in Google Scholar

58. Zaakouk M, Quinn C, Provenzano E, Boyd C, Callagy G, Elsheikh S, et al. Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland – on behalf of the UK National Coordinating Committee for Breast Pathology. Breast 2023; 70: 82–91. doi: 10.1016/j.breast.2023.06.005 ZaakoukM QuinnC ProvenzanoE BoydC CallagyG ElsheikhS Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland – on behalf of the UK National Coordinating Committee for Breast Pathology Breast 2023 70 82 91 10.1016/j.breast.2023.06.005 Open DOISearch in Google Scholar

59. Ivkovic-Kapic T, Knezevic-Usaj S, Moldvaji E, Jovanic I, Milovanovic Z, Milantijevic M, et al. Interlaboratory concordance in HER2 testing: results of a Serbian ring-study. J BUON 2019; 24: 1045–53. PMID: 31424659 Ivkovic-KapicT Knezevic-UsajS MoldvajiE JovanicI MilovanovicZ MilantijevicM Interlaboratory concordance in HER2 testing: results of a Serbian ring-study J BUON 2019 24 1045 53 31424659 Search in Google Scholar

60. Jonjić N, Mustać E, Tomić S, Jakić Razzumović J, Sarcević B, Blazicević, et al. Interlaboratory concordance in HER-2 positive breast cancer. Acta Clin Croat 2015; 54: 479–84. PMID: 27017723 JonjićN MustaćE TomićS Jakić RazzumovićJ SarcevićB Blazicević Interlaboratory concordance in HER-2 positive breast cancer Acta Clin Croat 2015 54 479 84 27017723 Search in Google Scholar

61. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94: 855–7. doi: 10.1093/jnci/94.11.855 RochePC SumanVJ JenkinsRB DavidsonNE MartinoS KaufmanPA Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 J Natl Cancer Inst 2002 94 855 7 10.1093/jnci/94.11.855 Open DOISearch in Google Scholar

62. Gennari A, André F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Ann Oncol 2021; 32: 1475–95. doi: 10.1016/j.annonc.2021.09.019 GennariA AndréF BarriosCH CortesJ de AzambujaE DeMicheleA ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Ann Oncol 2021 32 1475 95 10.1016/j.annonc.2021.09.019 Open DOISearch in Google Scholar

63. Curigliano G, Castelo-Branco, L Gennari A, Harbeck N, Criscitiello C, Trapani D on behalf of the CPG author group. ESMO Metastatic Breast Cancer Living Guideline, v1.1 May 2023. [internet]. [cited 2023 Dec 17]. Available at: https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline CuriglianoG Castelo-BrancoL GennariA HarbeckN CriscitielloC Trapani D on behalf of the CPG author group ESMO Metastatic Breast Cancer Living Guideline, v1.1 May 2023. [internet] [cited 2023 Dec 17]. Available at: https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline Search in Google Scholar

64. Lovasić IB, Koretić MB, Podolski P, Dedić Plavetić N, Silovski T, Pleština S, et al. [Clinical guidelines for diagnosis, treatment and monitoring of patients with invasive breast cancer – Croatian Oncology Society (BC-3 COS)]. [Croatian]. Liječ Vjesn 2022; 144: 295–305. doi: 10.26800/LV-144-9-10-2 LovasićIB KoretićMB PodolskiP Dedić PlavetićN SilovskiT PleštinaS [Clinical guidelines for diagnosis, treatment and monitoring of patients with invasive breast cancer – Croatian Oncology Society (BC-3 COS)]. [Croatian] Liječ Vjesn 2022 144 295 305 10.26800/LV-144-9-10-2 Open DOISearch in Google Scholar

65. European Medicines Agency. From laboratory to patient - the journey of a medicine assessed by EMA. [internet]. Eur Med Agency 2019. [cited 2023 Dec 18]. Available at: https://www.ema.europa.eu/en/documents/other/laboratory-patient-journey-centrally-authorised-medicine_en.pdf European Medicines Agency From laboratory to patient - the journey of a medicine assessed by EMA. [internet] Eur Med Agency 2019 [cited 2023 Dec 18]. Available at: https://www.ema.europa.eu/en/documents/other/laboratory-patient-journey-centrally-authorised-medicine_en.pdf Search in Google Scholar

66. Cufer T, Ciuleanu TE, Berzinec P, Galffy G, Jakopovic M, Jassem J, et al. Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: a Central European Cooperative Oncology Group analysis. Oncologist 2020; 25: e598–601. doi: 10.1634/theoncologist.2019-0523 CuferT CiuleanuTE BerzinecP GalffyG JakopovicM JassemJ Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: a Central European Cooperative Oncology Group analysis Oncologist 2020 25 e598 601 10.1634/theoncologist.2019-0523 Open DOISearch in Google Scholar

67. ESMO. ESMO-MCBS Scorecards. Scorecards for solid tumors. [internet]. [cited 2023 Dec 19]. Available at: https://www.esmo.org/guidelines/esmomcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards ESMO ESMO-MCBS Scorecards. Scorecards for solid tumors. [internet] [cited 2023 Dec 19]. Available at: https://www.esmo.org/guidelines/esmomcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards Search in Google Scholar